Cinrebafusp alfa Biosimilar – Anti-CD137 fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2292; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Title: Understanding the Structure and
Cinrebafusp alfa is a biosimilar of the anti-CD137 fusion protein, which has shown promising results in cancer immunotherapy. In this article, we will delve into the structure and activity of Cinrebafusp alfa, as well as its potential applications as a therapeutic target in cancer treatment.
Cinrebafusp alfa is a fusion protein composed of two distinct components – a human IgG1 antibody and a soluble form of the CD137 receptor. The human IgG1 antibody serves as the targeting moiety, while the soluble CD137 receptor acts as the effector molecule. The two components are linked together by a flexible linker, allowing for optimal binding and activation of CD137 receptor.
The CD137 receptor, also known as 4-1BB, is a member of the tumor necrosis factor receptor superfamily. It is expressed on the surface of activated T cells and natural killer cells, and its activation leads to enhanced T cell proliferation, survival, and cytokine production. Cinrebafusp alfa binds to tumor cells expressing CD137, leading to the activation of the receptor and subsequent immune response against the tumor.
In addition, Cinrebafusp alfa has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC). This mechanism involves the binding of the Fc region of the human IgG1 antibody to Fc receptors on immune cells, such as natural killer cells, which then target and kill tumor cells expressing CD137.
Cinrebafusp alfa has shown promising results in preclinical studies as a potential treatment for various types of cancer, including melanoma, breast cancer, and lung cancer. Its unique mechanism of action, targeting the CD137 receptor, makes it a promising therapeutic option for cancers that are resistant to other treatments.
In addition, Cinrebafusp alfa has been shown to have a synergistic effect when combined with other cancer treatments, such as chemotherapy and checkpoint inhibitors. This combination therapy has been shown to enhance the anti-tumor immune response and improve overall treatment outcomes.
Cinrebafusp alfa is currently being developed as a research grade product, which is intended for use in preclinical and clinical studies. It is produced using recombinant DNA technology, ensuring high purity and consistency in each batch. This allows for reliable and reproducible results in research studies.
In summary, Cinrebafusp alfa is a biosimilar of the anti-CD137 fusion protein with a unique structure and mechanism of action. Its ability to activate the CD137 receptor and induce ADCC makes it a promising candidate for cancer immunotherapy. Its potential applications in combination with other cancer treatments make it an exciting area of research in the field of oncology. As a research grade product, Cinrebafusp alfa provides a valuable tool for further understanding and developing this promising therapeutic option for cancer treatment.
ProteoGenix catalogue number PX-TA2292. For research use only.
Target: CD137; Clonality: Monoclonal Antibody; Applications: Block, WB, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | Block |
|---|---|---|---|---|---|---|---|---|---|
| CD137 |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
TNF receptor superfamily member 9 (TNFRSF9), also known as 4-1BB or CD137, is an activation-induced costimulatory receptor in immune-cell signalling. ABMIUM catalogue products linked below support research on TNFRSF9/CD137 biology.
Biological function: TNF receptor superfamily member 9 (TNFRSF9/CD137/4-1BB) is a member of the TNF receptor superfamily. Following lymphocyte activation, TNFRSF9 signalling can support T-cell clonal expansion, survival and differentiation and engages TRAF-dependent pathways including NF-kappaB. Its activation-linked expression and costimulatory role make CD137/4-1BB widely studied in T-cell and immune-regulation research.
